Progress Report 2011

Mel Spigelman, Co-Chair
Mission

To accelerate the discovery and development of new tuberculosis treatments by bringing together all stakeholder perspectives, including those of the patients, in TB Drug Research and Development

• Resource Gateway
• Catalyst of Dialog and Exchange
• Dynamic and Expanding Network
WGND Organization Updates

- Co-Chair (Elected Member)
- Co-Chair (TB Alliance)
- Secretariat
  - Biology/Targets
  - Candidates
  - Critical Knowledge/Tools
  - Clinical Trial Capacity
  - 2 X Community Representative
Total members: 197
up from 145 last year
Major Initiatives
WGND Initiatives 2011

- Website Enhancements
- Events
- Publications
- Networking

- PZA
- Strategic Planning Meeting
- Strategic Plan
- CPTR
- Stop TB Working Groups
**Phenotypic Hit-to-Lead**
University of Illinois, TB Alliance

**M. tuberculosis Protein Kinase Inhibitors**
Several chemical scaffolds with various PknA, PknB and PknG selectivity profiles. Vertex Pharmaceuticals, Incorporated

**Fungal metabolites**
Nigericin, University of Illinois at Chicago

**Actinomycete metabolites**
University of Illinois at Chicago, Myongji University

**DNA metabolism**
Nucleoside class
AstraZeneca R and D Bangalore

**Phenotypic hit to lead**
Multiple novel structural classes
Lilly TB Drug Discovery Initiative

**Novel hit-lead programs**
Novel structural class
Lilly TB Drug Discovery Initiative

**Protein Splicing Inhibitors**
Boston Biomedical Research Institute

**Combinatorial Biosynthetic Compounds**
Shaw Environmental and University of Illinois at Chicago

**Folate Biosynthesis Inhibitors**
AstraZeneca, TB Alliance

**Phenotypic Hit-to-Lead**
AstraZeneca, TB Alliance

**Malate Synthase Inhibitors**
GlaxoSmithKline, Texas A&M University, TB Alliance

**Menadione Synthase Inhibitors**
Colorado State University, TB Alliance

**Inhibitors of Mycobacterium Tuberculosis Energy Metabolism**
Various Classes
UPenn and TB Alliance

**Inhibitors of isopenicillin biosynthesis**
Lilly TB Drug Discovery Initiative

**Nitroimidazoles**
Nitroimidazoles
TB Alliance, University of Houston, University of Illinois

**Diarylquinolines**
Diarylquinoline
TB Alliance, University of Auckland, Tibotec

**Rimnophenazines**
Rimnophenazines antibiotic
TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois

**InhA Inhibitors**
Novel structural class
GlaxoSmithKline, TB Alliance

**LeuRS inhibitors**
Oxaboroles
Aracor Pharmaceuticals

**Mycobacterial Gyrase Inhibitors**
Novel structural class
TB Alliance, GlaxoSmithKline

**Pyrazinamide Analogs**
Pyrazinamide/nicotinamide analogs
TB Alliance/Yonsei University

**TL1 Inhibitors**
Capraarumycin
Sequella

**MTOP inhibitors**
Novel structural class
tAstraZeneca R and D Bangalore

**GyrB Inhibitors**
AstraZeneca, TB Alliance

**SCAR - Ruthenium (II) phosphate/dilinmine/picolinate complexes: Inorganic compounds as agents against tuberculosis**
Inorganic Compounds
FAPESP/Brazil

**Spectinamides**
Spectinomycin analogs
St Jude Children’s Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbiotix
Please Join the conversation